BiC – Biomarkers Commercialisation: an Interreg Baltic Sea Region project to foster the commercialisation of biomarkers
Biomarkers, an ever growing set of indicators of the changes happening within tissues, cells or fluids which allows to predict illnesses, provide highly accurate diagnostics or adapt treatments to each individual patient to provide better and personalised medicine.
The discovery of biomarkers is becoming increasingly important in research and industry, expected to increase economic growth and to open up new possibilities for diagnostics and treatment. Despite the strong potential of biomarkers for new markets, there is a general lack of experience on how to bring biomarkers through the innovation process and into clinical practice. The challenges for market uptake are significant, as the development and commercialisation of biomarkers is time consuming, difficult and expensive.
The Interreg Baltic Sea Region project BiC – Biomarker Commercialisation will tackle these challenges by setting up a tool and platform to accompany the biomarker development pathway at every stage, and bring the industry, including pharmaceutical and diagnostic enterprises, SMEs and investors, to participate as early as possible in the development process.
Under the lead of the Danish Ideklinikken/Aalborg University Hospital, the project brings together nine partners from the Baltic Sea Region:
- Danish Ideklinikken/Aalborg University Hospital
- Biopeople/University of Copenhagen (Denmark)
- Tartu Biotechnology Park OÜ (Estonia)
- University of Turku (Finland)
- Turku Science Park Ltd (Finland)
- ScanBalt (Denmark)
- BioCon Valley® GmbH (Germany)
- Vilnius University (Lithuania)
- Wroclaw Technology Park (Poland).
BIC will design and develop :
- a biomarker development tool for researchers
- a screening and selection guide for TTOs
- a framework for technology translation into clinical setting
- new business model templates
- a biomarker platform with access to the tools and
- technology presentations for match making
By enabling better and more efficient commercialisation of biomarkers, BiC will contribute in improving realisation and competitiveness of biomarkers within the Baltic Sea Region and on the long term will benefit hospitals and patients to provide affordable and personalised healthcare.
BiC is a pillar in the EUSBSR flagship project “Health Region“. BiC runs from October 2017 until September 2020 with a total budget of EUR 2,55 million.
BiC receives EUR 1,96 million of co-financing from the European Regional Development Fund through the Interreg Baltic Sea Region Programme.
Contact person: Valerie Daussin Laurent, tel + 45 97 66 62 97, e-mail: email@example.com
20 September 2018
Bioagora 2018 (Copenhagen)
19 September 2018
STZ OcuTox: Drug development know-how
12 September 2018
Good industry performance lifted spirits in the HealthBIO conference